Clinical Trials Logo

Placenta Accreta Spectrum clinical trials

View clinical trials related to Placenta Accreta Spectrum.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04927988 Withdrawn - Clinical trials for Placenta Accreta Spectrum

Blood Components Changes by Using of Ringer's Lactated as Detergent In Autologous Blood Cell Transfusion

Start date: October 2021
Phase: N/A
Study type: Interventional

Placenta accreta spectrum (PAS) disorders are associated with increased maternal morbidity and mortality related to life-threatening hemorrhage, and greater potential need for blood transfusion. Clinical evidences have confirmed that the use of autologous blood cell transfusion is safe and effective for patients with obstetric haemorrhage. Normal saline is the solution recommended for red cell washing, administration and salvage. However, there is growing concern that normal saline is more toxic than balanced, buffered crystalloids such as Lactated Ringer's and Plasma-Lyte. The purpose of this study is to evaluate the blood components using of Ringer's Lactated by a prospective, single-center, open, and single-arm clinical trial.